{
  "schemaVersion": "2.0",
  "lastUpdated": "2025-01-09",
  
  "substance": {
    "id": "mdma_001",
    "name": "MDMA",
    "aliases": [
      "Ecstasy",
      "Molly",
      "Adam",
      "XTC",
      "Mandy",
      "The Love Drug"
    ],
    "classification": {
      "primary": "entactogen_empathogen",
      "secondary": ["stimulant_psychedelic", "phenethylamine"],
      "mechanism": "monoamine_transporter_reversal",
      "receptorAffinity": {
        "SERT": "high",
        "NET": "high",
        "DAT": "moderate",
        "5HT": "moderate",
        "DA": "moderate",
        "muscarinic": "low",
        "histamine": "low",
        "adrenergic": "low"
      },
      "notClassicalPsychedelic": true,
      "structuralSimilarity": ["amphetamines", "mescaline"]
    },
    "neurotransmitterEffects": {
      "increasesExtracellular": [
        {
          "neurotransmitter": "serotonin",
          "mechanism": "reverses_SERT"
        },
        {
          "neurotransmitter": "norepinephrine",
          "mechanism": "reverses_NET"
        },
        {
          "neurotransmitter": "dopamine",
          "mechanism": "reverses_DAT"
        }
      ],
      "hormonalEffects": [
        {
          "hormone": "cortisol",
          "effect": "increases"
        },
        {
          "hormone": "arginine_vasopressin",
          "effect": "increases"
        },
        {
          "hormone": "oxytocin",
          "effect": "releases",
          "note": "May explain empathic and pro-social effects"
        }
      ]
    },
    "prevalenceData": {
      "switzerland": {
        "value": 3.5,
        "unit": "percent",
        "population": "15-34 year-olds",
        "context": "At least one recreational dose",
        "citations": ["vollenweider_1998"]
      },
      "england": {
        "value": {"min": 4.5, "max": 6},
        "unit": "percent",
        "population": "14-15 year-olds",
        "citations": ["vollenweider_1998"]
      },
      "emergencyRoomVisits": {
        "rate": 1,
        "unit": "percent",
        "year": 2020,
        "context": "Of all users seeking emergency care",
        "citations": ["canady_2023"]
      },
      "globalStatus": "Among most commonly used illicit substances worldwide",
      "toxicityPresentations": "Growing availability, unknown composition, megadoses (up to 300mg/pill), higher purity, higher total dose consumed (500mg/session)"
    },
    "dosing": {
      "therapeutic": {
        "range": {"min": 75, "max": 225, "unit": "mg"},
        "route": "oral",
        "context": "Psychedelic-assisted therapy",
        "citations": ["sarparast_2022"]
      },
      "clinical": {
        "range": {"min": 70, "max": 150, "unit": "mg"},
        "perKg": {"min": 1.35, "max": 1.8, "unit": "mg/kg"},
        "preparation": "25mg opaque gelatin capsules of pharmaceutically pure MDMA hydrochloride",
        "commonDoses": [
          {"value": 100, "unit": "mg", "capsules": 4},
          {"value": 125, "unit": "mg", "capsules": 5}
        ],
        "citations": ["papaseit_2018", "atila_2024"]
      },
      "recreational": {
        "typical": {"min": 75, "max": 150, "unit": "mg"},
        "perKg": {"min": 1, "max": 2, "unit": "mg/kg"},
        "common": {"min": 75, "max": 125, "unit": "mg"},
        "approximately": {"value": 125, "unit": "mg"},
        "citations": ["baumeister_2015", "papaseit_2018", "henriquez_2023"]
      },
      "investigational": {
        "healthyVolunteers": {"value": 1.7, "unit": "mg/kg"},
        "context": "Examining acute effects in MDMA-naive volunteers",
        "citations": ["vollenweider_1998"]
      },
      "doseResponseRelationship": {
        "linearity": "non_linear",
        "note": "No simple correlation between dose ingested and physiological effects",
        "mechanism": "Inhibits its own metabolism",
        "citations": ["henriquez_2023", "papaseit_2018"]
      },
      "illicitMarketConcern": {
        "increasingPotency": "Tablets often contain 2-3x typical recreational dose",
        "megadosePills": "Up to 300mg/pill",
        "highSessionDose": "Up to 500mg/session reported",
        "citations": ["papaseit_2018"]
      },
      "redosingRisk": {
        "concern": "high",
        "mechanism": "Non-linear kinetics and self-inhibition of metabolism",
        "consequence": "Significantly increased toxicity risk",
        "citations": ["dourron_2023", "henriquez_2023", "papaseit_2018", "poyatos_2023"]
      },
      "addictionPotential": {
        "highDose": {
          "threshold": "≥3 mg/kg",
          "risk": "May have addictive potential",
          "citation": "pantoni_2022"
        },
        "amnesia": "High doses can produce amnesia",
        "generalRisk": "Lower than many substances but present"
      }
    },
    "pharmacokinetics": {
      "absorption": {
        "route": "oral_primary",
        "bioavailability": "variable"
      },
      "metabolism": {
        "primaryEnzyme": "CYP2D6",
        "otherEnzymes": ["CYP1A2", "CYP2B6", "CYP2C19"],
        "geneticPolymorphisms": {
          "relevant": true,
          "poorMetabolizers": {
            "frequency": "5-10% of population",
            "effect": "Higher plasma concentrations of MDMA",
            "consequence": "Increased risk of toxicity",
            "citations": ["sarparast_2022", "papaseit_2018"]
          },
          "ultraRapidMetabolizers": {
            "frequency": "1-2% of population",
            "effect": "Lower plasma concentrations",
            "consequence": "Potentially reduced effects"
          }
        },
        "selfInhibition": {
          "description": "MDMA inhibits its own metabolism",
          "consequence": "Non-linear pharmacokinetics",
          "implication": "Repeated dosing dramatically increases exposure",
          "citations": ["henriquez_2023", "papaseit_2018"]
        }
      },
      "onset": {
        "oral": {"min": 30, "max": 60, "unit": "minutes"}
      },
      "peak": {
        "oral": {"min": 60, "max": 120, "unit": "minutes"}
      },
      "duration": {
        "acute": {"min": 3, "max": 6, "unit": "hours"},
        "aftereffects": {"min": 24, "max": 72, "unit": "hours"}
      },
      "elimination": "renal"
    },
    "subjectiveEffects": {
      "characteristic": [
        "euphoria",
        "well_being",
        "increased_empathy",
        "pro_social_effects",
        "emotional_openness",
        "enhanced_sensory_perception",
        "altered_mood",
        "altered_perception",
        "altered_cognition"
      ],
      "variability": {
        "high": true,
        "factors": ["individual_sensitivity", "genetic_polymorphisms", "setting", "dose"]
      }
    },
    "therapeuticApplications": {
      "ptsd": {
        "status": "FDA_breakthrough_therapy_designation",
        "evidence": "Strong from clinical trials",
        "format": "MDMA-assisted psychotherapy"
      },
      "otherConditions": [
        "anxiety",
        "depression",
        "relationship_issues"
      ],
      "mechanism": "Empathogenic effects facilitate therapeutic processing"
    },
    "toleranceDevelopment": {
      "rate": "moderate",
      "note": "Some users report need for higher doses with regular use",
      "crossTolerance": "minimal_with_classical_psychedelics"
    }
  },

  "riskFactors": [
    {
      "id": "rf_mdma_high_dose_001",
      "name": "High Dose",
      "category": "dosage",
      "severity": "high",
      "description": "Higher doses significantly increase risk of adverse events",
      "specificRisks": [
        "hyperthermia",
        "hyponatremia",
        "serotonin_syndrome",
        "cardiovascular_complications",
        "neurotoxicity",
        "cognitive_impairment",
        "amnesia"
      ],
      "doseThresholds": {
        "increasedRisk": ">150 mg",
        "highRisk": ">200 mg",
        "addictionPotential": "≥3 mg/kg (~210mg for 70kg person)"
      },
      "citations": ["dourron_2023", "bremler_2023", "henriquez_2023", "pantoni_2022"]
    },
    {
      "id": "rf_mdma_repeated_dosing_001",
      "name": "Repeated Consumption/Redosing",
      "category": "behavioral",
      "severity": "very_high",
      "description": "Taking multiple doses in short period dramatically increases toxicity risk",
      "mechanism": "Non-linear kinetics and self-inhibition of metabolism",
      "consequence": "Exponential increase in plasma levels and adverse effects",
      "citations": ["dourron_2023", "henriquez_2023", "papaseit_2018", "poyatos_2023"]
    },
    {
      "id": "rf_mdma_female_sex_001",
      "name": "Female Sex",
      "category": "demographic",
      "subcategory": "biological_sex",
      "severity": "moderate_to_high",
      "description": "Women more susceptible to negative effects of MDMA",
      "specificEffects": {
        "plasmaConcentrations": "Higher than men",
        "subjectiveEffects": "More intense",
        "perceptualChanges": "More frequent and intense",
        "anxiety": "More frequent and intense",
        "depression": "More frequent and intense",
        "acuteAdverseEffects": "More frequent",
        "subacuteAdverseEffects": "More frequent",
        "comedownEffects": "More adverse mood effects",
        "hyponatremiaRisk": {
          "elevated": true,
          "mechanism": "Higher plasma MDMA concentrations in women with lower BMIs"
        }
      },
      "citations": ["papaseit_2018", "atila_2024", "parrott_2014"]
    },
    {
      "id": "rf_mdma_low_bmi_001",
      "name": "Low Body Mass Index",
      "category": "physiological",
      "severity": "moderate_to_high",
      "description": "Lower BMI associated with higher hyponatremia risk",
      "mechanism": "Higher plasma MDMA concentrations",
      "interactionWithSex": "Particularly relevant for women",
      "specificRisk": "hyponatremia",
      "citations": ["atila_2024"]
    },
    {
      "id": "rf_mdma_hot_environment_001",
      "name": "High Temperature Environment",
      "category": "environmental",
      "severity": "high",
      "description": "Hot environments dramatically increase hyperthermia risk",
      "typicalSettings": ["nightclubs", "music_festivals", "raves"],
      "mechanism": [
        "MDMA inhibits brain's temperature regulation",
        "Physical exertion (dancing) generates heat",
        "Crowded environments reduce heat dissipation",
        "Dehydration"
      ],
      "specificRisks": [
        "hyperthermia",
        "dehydration",
        "hyponatremia_from_overhydration"
      ],
      "citations": ["barnett_2021", "vollenweider_1998", "atila_2024", "papaseit_2018"]
    },
    {
      "id": "rf_mdma_physical_exertion_001",
      "name": "Physical Exertion",
      "category": "behavioral",
      "severity": "high",
      "description": "Prolonged dancing or physical activity increases risks",
      "typicalContext": "Dancing in clubs/festivals",
      "specificRisks": [
        "hyperthermia",
        "dehydration",
        "hyponatremia",
        "exhaustion"
      ],
      "interactionsWith": ["rf_mdma_hot_environment_001"],
      "citations": ["barnett_2021", "atila_2024"]
    },
    {
      "id": "rf_mdma_overhydration_001",
      "name": "Overhydration with Hypotonic Fluids",
      "category": "behavioral",
      "severity": "high",
      "description": "Drinking excessive water leads to severe hyponatremia",
      "mechanism": [
        "MDMA causes inappropriate ADH secretion",
        "Increased water retention",
        "Dilutional hyponatremia"
      ],
      "prevalence": {
        "unrestricted": {
          "value": 37,
          "unit": "percent",
          "context": "With unrestricted fluid intake in controlled study",
          "citation": "atila_2024"
        },
        "restricted": {
          "value": 31,
          "unit": "percent",
          "context": "With fluid restriction intervention",
          "citation": "atila_2024"
        }
      },
      "severeCases": {
        "sodiumRange": {"min": 101, "max": 130, "unit": "mEq/L"},
        "presentation": "Life-threatening",
        "citation": "atila_2024"
      },
      "citations": ["barnett_2021", "atila_2024", "edwards_2023"]
    },
    {
      "id": "rf_mdma_psychiatric_history_001",
      "name": "Pre-existing Mental Health Conditions",
      "category": "psychiatric",
      "severity": "moderate_to_high",
      "description": "History of psychiatric disorders increases vulnerability",
      "specificConditions": [
        "depression",
        "anxiety_disorders",
        "psychotic_disorders",
        "bipolar_disorder"
      ],
      "risks": [
        "exacerbation_of_symptoms",
        "prolonged_psychotic_episodes",
        "increased_depression_post_use",
        "suicidal_ideation"
      ],
      "citations": ["parrott_2014", "ghaznavi_2025", "strassman_1984"]
    },
    {
      "id": "rf_mdma_cardiovascular_001",
      "name": "Pre-existing Cardiovascular Conditions",
      "category": "physiological",
      "subcategory": "cardiovascular",
      "severity": "critical",
      "description": "Heart conditions pose serious risk with MDMA",
      "mechanism": "MDMA increases heart rate and blood pressure",
      "specificConditions": [
        "uncontrolled_hypertension",
        "coronary_artery_disease",
        "arrhythmias",
        "recent_myocardial_infarction",
        "heart_failure",
        "labile_hypertonia"
      ],
      "specificRisks": [
        "myocardial_infarction",
        "hypertensive_crisis",
        "arrhythmia",
        "sudden_cardiac_death"
      ],
      "contraindicationType": "absolute_if_severe",
      "citations": ["vollenweider_1998", "makunts_2023", "expert_opinion_nd"]
    },
    {
      "id": "rf_mdma_polydrug_001",
      "name": "Polydrug Use",
      "category": "behavioral",
      "subcategory": "substance_use",
      "severity": "very_high",
      "description": "Combining MDMA with other substances dramatically increases risk",
      "prevalence": {
        "alcoholCoUse": {
          "value": 81,
          "unit": "percent",
          "context": "Ecstasy users who also consume alcohol",
          "citation": "edwards_2023"
        },
        "deathsInvolvingOtherDrugs": {
          "value": 66,
          "unit": "percent",
          "context": "MDMA/ecstasy-related deaths in England and Wales",
          "citation": "edwards_2023"
        }
      },
      "dangerousCombinations": [
        {
          "substances": ["MDMA", "alcohol"],
          "risk": "Increased adverse effects, dehydration, impaired judgment"
        },
        {
          "substances": ["MDMA", "stimulants"],
          "risk": "Severe cardiovascular stress, hyperthermia"
        },
        {
          "substances": ["MDMA", "SSRIs"],
          "risk": "Serotonin syndrome",
          "severity": "critical"
        },
        {
          "substances": ["MDMA", "MAOIs"],
          "risk": "Severe serotonin syndrome",
          "severity": "fatal",
          "contraindicationType": "absolute"
        },
        {
          "substances": ["MDMA", "antiretrovirals"],
          "specific": "ritonavir",
          "risk": "Overdose due to liver metabolism interactions",
          "severity": "critical"
        }
      ],
      "citations": ["sarparast_2022", "makunts_2023", "atila_2024", "papaseit_2018", "barnett_2021", "piercey_2024"]
    },
    {
      "id": "rf_mdma_fatigue_001",
      "name": "Fatigue and Exhaustion",
      "category": "physiological",
      "severity": "moderate",
      "description": "Pre-existing fatigue predisposes to negative outcomes",
      "citations": ["vollenweider_1998"]
    },
    {
      "id": "rf_mdma_illicit_drug_history_001",
      "name": "History of Illicit Drug Abuse",
      "category": "psychiatric",
      "subcategory": "substance_use",
      "severity": "moderate_to_high",
      "description": "History of drug abuse increases risk for MDMA-related sequelae",
      "contraindicationType": "relative",
      "citations": ["vollenweider_1998"]
    }
  ],

  "contraindications": {
    "absolute": [
      {
        "id": "contra_mdma_abs_001",
        "condition": "Severe cardiovascular disease",
        "description": "Including recent MI, unstable angina, severe arrhythmias, uncontrolled hypertension",
        "rationale": "MDMA increases heart rate and blood pressure, risking life-threatening complications",
        "citations": ["baumeister_2015", "vollenweider_1998", "expert_opinion_nd"]
      },
      {
        "id": "contra_mdma_abs_002",
        "condition": "Active psychotic disorders",
        "description": "Including schizophrenia, schizoaffective disorder, bipolar with psychotic features",
        "rationale": "Can exacerbate symptoms and trigger prolonged psychotic episodes",
        "citations": ["ghaznavi_2025", "strassman_1984", "parrott_2014"]
      },
      {
        "id": "contra_mdma_abs_003",
        "condition": "Active suicidality",
        "description": "Recent suicide attempts or active suicidal ideation",
        "rationale": "Risk of increased depression and potential for suicide, especially during comedown",
        "citations": ["parrott_2014", "sarparast_2022"]
      },
      {
        "id": "contra_mdma_abs_004",
        "condition": "Concurrent use of MAOIs",
        "description": "Monoamine oxidase inhibitors including moclobemide",
        "rationale": "Can lead to severe, potentially fatal serotonin syndrome",
        "severity": "critical",
        "citations": ["barnett_2021", "malcolm_2022"]
      },
      {
        "id": "contra_mdma_abs_005",
        "condition": "Pregnancy",
        "rationale": "Potential risks to fetal development unknown",
        "citations": ["baumeister_2015"]
      },
      {
        "id": "contra_mdma_abs_006",
        "condition": "Breastfeeding",
        "rationale": "Potential risks to infant, drug may pass into breast milk",
        "citations": ["friguls_2010"]
      }
    ],
    "relative": [
      {
        "id": "contra_mdma_rel_001",
        "condition": "History of seizures",
        "description": "Epilepsy or seizure disorder",
        "rationale": "MDMA can lower seizure threshold",
        "requiredPrecautions": ["Careful evaluation", "Medical supervision", "Risk-benefit assessment"],
        "citations": ["baumeister_2015", "atila_2024"]
      },
      {
        "id": "contra_mdma_rel_002",
        "condition": "Liver or kidney disease",
        "description": "Hepatic or renal impairment",
        "rationale": "MDMA metabolized in liver and excreted by kidneys; impairment may increase adverse effects",
        "requiredPrecautions": ["Medical evaluation", "Dose adjustment", "Monitoring"],
        "citations": ["baumeister_2015"]
      },
      {
        "id": "contra_mdma_rel_003",
        "condition": "Anxiety disorders",
        "description": "Pre-existing anxiety disorders",
        "rationale": "MDMA can potentially exacerbate anxiety symptoms",
        "requiredPrecautions": ["Careful monitoring", "Therapeutic support"],
        "citations": ["breeksema_2022", "parrott_2014"]
      },
      {
        "id": "contra_mdma_rel_004",
        "condition": "Depression",
        "description": "Major depressive disorder",
        "rationale": "Temporary period of depression, anxiety, insomnia after acute effects; may increase suicidal thoughts",
        "requiredPrecautions": ["Careful screening", "Post-session monitoring", "Integration support"],
        "citations": ["lacroix_2024", "parrott_2014"]
      },
      {
        "id": "contra_mdma_rel_005",
        "condition": "Use of SSRIs or serotonergic medications",
        "description": "Concurrent use of medications affecting serotonin",
        "rationale": "Increased risk of serotonin syndrome",
        "requiredPrecautions": ["Medical supervision", "Possible dose adjustment", "Careful monitoring"],
        "citations": ["barnett_2021", "baggott_nd"]
      },
      {
        "id": "contra_mdma_rel_006",
        "condition": "Mild to moderate cardiovascular issues",
        "description": "Controlled hypertension, mild heart conditions",
        "rationale": "Potential for increased blood pressure and heart rate",
        "requiredPrecautions": ["Careful monitoring", "Risk assessment", "Medical clearance"],
        "citations": ["vollenweider_1998", "hysek_2010"]
      },
      {
        "id": "contra_mdma_rel_007",
        "condition": "Electrolyte imbalances",
        "description": "History of electrolyte imbalances",
        "rationale": "Increased risk of hyponatremia",
        "requiredPrecautions": ["Baseline electrolyte testing", "Fluid restriction", "Monitoring"],
        "citations": ["expert_opinion_nd"]
      },
      {
        "id": "contra_mdma_rel_008",
        "condition": "Antiretroviral medication use",
        "description": "Particularly ritonavir",
        "rationale": "Liver metabolism interactions can lead to overdose",
        "requiredPrecautions": ["Dose adjustment", "Medical supervision"],
        "citations": ["sarparast_2022"]
      }
    ]
  },

  "adverseEvents": {
    "acute": {
      "psychological": [
        {
          "id": "ae_mdma_anxiety_acute_001",
          "name": "Anxiety",
          "severity": "mild_to_moderate",
          "prevalence": "Most common psychological adverse event in acute phase",
          "description": "Anxiety during or shortly after MDMA administration",
          "management": ["Reassurance", "Calm environment", "Breathing exercises"],
          "citations": ["breeksema_2022"]
        },
        {
          "id": "ae_mdma_mood_changes_001",
          "name": "Mood Changes",
          "description": "Both positive and negative mood alterations",
          "manifestations": {
            "positive": ["emotional_excitement", "heightened_mood", "sensitivity"],
            "negative": ["apprehensiveness", "anxiety", "fear_of_losing_control"]
          },
          "severeCases": ["paranoia", "fear", "thoughts_of_death", "panic"],
          "citations": ["parrott_2014"]
        },
        {
          "id": "ae_mdma_memory_acute_001",
          "name": "Memory Impairment",
          "timeframe": "acute",
          "description": "Transient memory impairment during effects",
          "specificity": "Primarily affects memory; executive functions and attention mostly unaffected",
          "types": [
            {
              "type": "false_memories",
              "description": "Increased for similar but less important details",
              "timing": "After delay"
            },
            {
              "type": "true_memory_impairment",
              "description": "Decreased accuracy of actual memories"
            }
          ],
          "risk": "May lead to dangerous re-dosing due to uncertainty about amount consumed",
          "citations": ["basedow_2024", "kloft_2022", "kuypers_2005"]
        },
        {
          "id": "ae_mdma_other_psych_acute_001",
          "name": "Other Psychological Symptoms",
          "symptoms": [
            "lack_of_appetite",
            "balance_issues",
            "restlessness",
            "restless_legs",
            "difficulty_concentrating",
            "muscle_aches",
            "fatigue"
          ],
          "citations": ["papaseit_2018", "hysek_2010", "breeksema_2022"]
        }
      ],
      "physiological": [
        {
          "id": "ae_mdma_cardiovascular_acute_001",
          "name": "Cardiovascular Effects",
          "description": "Transient increases in heart rate and blood pressure",
          "severity": "moderate",
          "typicalEffects": {
            "heartRate": "increased",
            "bloodPressure": "increased_moderately"
          },
          "severeCases": [
            {
              "condition": "hypertension",
              "description": "Significant blood pressure elevation"
            },
            {
              "condition": "myocardial_infarction",
              "rarity": "rare_but_documented"
            },
            {
              "condition": "arrhythmia",
              "rarity": "uncommon"
            },
            {
              "condition": "severe_hypertensive_reaction",
              "prevalence": "One subject in study",
              "citation": "vollenweider_1998"
            }
          ],
          "citations": ["makunts_2021", "makunts_2023", "breeksema_2022", "hysek_2010", "vollenweider_1998"]
        },
        {
          "id": "ae_mdma_hyperthermia_001",
          "name": "Hyperthermia",
          "severity": "critical",
          "description": "Dangerous increase in body temperature",
          "dangerLevel": "Leading cause of MDMA-related deaths",
          "canOccurWith": "Even modest doses",
          "mechanism": "Inhibition of brain's temperature regulation center",
          "exacerbatingFactors": [
            "hot_environments",
            "physical_exertion",
            "dancing",
            "crowded_spaces",
            "dehydration"
          ],
          "otherSymptoms": [
            "feeling_cold",
            "hot_flashes",
            "increased_sweating"
          ],
          "citations": ["curry_2018", "papaseit_2018", "hysek_2010", "vollenweider_1998"]
        },
        {
          "id": "ae_mdma_hyponatremia_001",
          "name": "Hyponatremia",
          "severity": "severe",
          "description": "Dangerously low sodium levels",
          "clinicalDefinition": "Plasma sodium <135 mEq/L",
          "prevalence": [
            {
              "value": 37,
              "unit": "percent",
              "context": "Single dose, unrestricted fluid intake in controlled study",
              "citation": "atila_2024"
            },
            {
              "value": 31,
              "unit": "percent",
              "context": "With fluid restriction intervention",
              "citation": "atila_2024"
            }
          ],
          "severeCases": {
            "sodiumRange": {"min": 101, "max": 130, "unit": "mEq/L"},
            "presentation": "Life-threatening",
            "canOccurFrom": "Single dose"
          },
          "mechanism": [
            "Inappropriate ADH secretion",
            "Excessive water intake",
            "Increased water retention",
            "Physical exertion with hypotonic fluid replacement"
          ],
          "riskFactors": [
            "Female sex",
            "Low BMI",
            "Hot environments",
            "Overhydration"
          ],
          "symptoms": {
            "mild": ["nausea", "headache", "confusion"],
            "moderate": ["vomiting", "muscle_weakness"],
            "severe": ["seizures", "coma", "death"]
          },
          "prevention": [
            "Fluid restriction during session",
            "Education about appropriate hydration",
            "Avoid hypotonic fluids",
            "Monitor environment temperature"
          ],
          "citations": ["atila_2024", "barnett_2021", "edwards_2023"]
        },
        {
          "id": "ae_mdma_serotonin_syndrome_001",
          "name": "Serotonin Syndrome",
          "severity": "critical",
          "description": "Potentially life-threatening condition from excessive serotonin",
          "prevalence": "Rare in clinical settings; more common with polydrug use",
          "symptoms": {
            "autonomic": [
              "hyperthermia",
              "tachycardia",
              "hypertension",
              "diaphoresis"
            ],
            "neuromuscular": [
              "muscle_rigidity",
              "tremor",
              "hyperreflexia"
            ],
            "cognitive": [
              "agitation",
              "confusion"
            ],
            "severe": [
              "seizures",
              "death"
            ]
          },
          "triggeringCombinations": [
            "MDMA + SSRIs",
            "MDMA + MAOIs",
            "MDMA + other serotonergic drugs"
          ],
          "citations": ["maxwell_2005", "makunts_2023", "piercey_2024"]
        },
        {
          "id": "ae_mdma_nausea_001",
          "name": "Nausea",
          "severity": "mild_to_moderate",
          "prevalence": "common",
          "citations": ["papaseit_2018"]
        }
      ]
    },
    "longTerm": {
      "psychological": [
        {
          "id": "ae_mdma_cognitive_lt_001",
          "name": "Cognitive Impairment",
          "timeframe": "long_term",
          "controversy": "Remains under debate",
          "prevalence": "Primarily in heavy users if exists",
          "specificDeficits": [
            "memory_deficits",
            "attention_problems",
            "verbal_learning_impairment",
            "non_verbal_learning_impairment",
            "psychomotor_function_deficits",
            "executive_function_deficits",
            "short_term_memory_issues",
            "working_memory_issues"
          ],
          "duration": "Can persist up to two years after cessation",
          "metaAnalysisFindings": "Deficits in memory and higher cognition documented",
          "citations": ["parrott_2014", "mithoefer_2013", "baumeister_2015", "barnett_2021"]
        },
        {
          "id": "ae_mdma_psychiatric_lt_001",
          "name": "Psychiatric Problems",
          "timeframe": "long_term",
          "description": "Various psychiatric issues with regular use",
          "conditions": [
            {
              "condition": "sleep_disturbances",
              "prevalence": "common"
            },
            {
              "condition": "mood_disorders",
              "prevalence": "common"
            },
            {
              "condition": "anxiety_disorders",
              "prevalence": "common"
            },
            {
              "condition": "increased_impulsivity",
              "prevalence": "documented"
            },
            {
              "condition": "depression",
              "prevalence": "common"
            }
          ],
          "surveyFindings": {
            "lowMood": {
              "value": 83,
              "unit": "percent",
              "context": "Regular MDMA users between sessions"
            },
            "impairedConcentration": {
              "value": 80,
              "unit": "percent",
              "context": "Regular MDMA users between sessions"
            }
          },
          "adolescentRisk": "May manifest as persistent depression or increased vulnerability to neuropsychiatric conditions",
          "citations": ["parrott_2014", "maxwell_2005"]
        },
        {
          "id": "ae_mdma_comedown_001",
          "name": "Post-MDMA 'Blues' or 'Midweek Blues'",
          "timeframe": "subacute",
          "timing": "Following period of mood activation",
          "description": "Period of neurochemical depletion",
          "symptoms": [
            "anhedonia",
            "lethargy",
            "anger",
            "depression",
            "low_mood"
          ],
          "sexDifferences": "Women report more adverse mood effects than men",
          "observedIn": "Both MDMA and placebo groups but more pronounced with MDMA",
          "citations": ["parrott_2014", "breeksema_2022"]
        },
        {
          "id": "ae_mdma_dependence_001",
          "name": "Dependence and Problematic Use",
          "description": "Sense of use being 'out of control' or difficulty stopping",
          "prevalence": {
            "outOfControl": {
              "value": 8,
              "unit": "percent",
              "context": "Participants using MDMA at least monthly in previous 6 months",
              "comparison": "1% of those using less than monthly"
            }
          },
          "addictionPotential": {
            "highDose": "≥3 mg/kg may have addictive potential",
            "general": "Not considered as addictive as many other drugs"
          },
          "citations": ["banta-green_2005", "pantoni_2022"]
        },
        {
          "id": "ae_mdma_tolerance_001",
          "name": "Tolerance",
          "description": "Some users report need for higher doses with repeated use",
          "citations": ["ingrosso_2024", "bonnet_2015"]
        }
      ],
      "physiological": [
        {
          "id": "ae_mdma_neurotoxicity_001",
          "name": "Neurotoxicity",
          "description": "Particularly to serotonergic neurons",
          "evidence": "Documented in laboratory animals",
          "humanEvidence": "Some studies suggest persistent serotonergic neurotoxicity",
          "consequence": "Long-lasting brain dysfunction",
          "controversy": "Extent in humans debated",
          "citations": ["curry_2018", "parrott_2014"]
        },
        {
          "id": "ae_mdma_hormonal_001",
          "name": "Hormonal Changes",
          "description": "Powerful neurohormonal effects",
          "affectedHormones": [
            "cortisol (increased)",
            "oxytocin (increased)",
            "testosterone (increased)"
          ],
          "citations": ["parrott_2014"]
        }
      ]
    }
  },

  "drugInteractions": [
    {
      "id": "interaction_mdma_ssri_001",
      "drug1": "MDMA",
      "drug2": "SSRIs",
      "severity": "high",
      "risk": "Serotonin syndrome",
      "mechanism": "Excessive serotonin accumulation",
      "contraindicationType": "relative",
      "requiredPrecautions": ["Medical supervision", "Dose adjustment", "Close monitoring"],
      "citations": ["barnett_2021", "baggott_nd"]
    },
    {
      "id": "interaction_mdma_maoi_001",
      "drug1": "MDMA",
      "drug2": "MAOIs",
      "severity": "critical",
      "risk": "Severe serotonin syndrome",
      "mechanism": "Profound increase in serotonin levels",
      "outcome": "Potentially fatal",
      "contraindicationType": "absolute",
      "includingDrugs": ["moclobemide", "traditional_MAOIs"],
      "documentation": "Repeatedly documented cases including with moclobemide for strategic potentiation",
      "citations": ["barnett_2021", "malcolm_2022"]
    },
    {
      "id": "interaction_mdma_antiretroviral_001",
      "drug1": "MDMA",
      "drug2": "Antiretrovirals",
      "specific": "ritonavir",
      "severity": "critical",
      "risk": "Overdose",
      "mechanism": "Liver metabolism interactions",
      "citations": ["sarparast_2022"]
    },
    {
      "id": "interaction_mdma_adrenergic_001",
      "drug1": "MDMA",
      "drug2": "Adrenergic agents",
      "severity": "uncertain",
      "note": "Interaction warrants additional research",
      "relevance": "Hypertension and antipyretic management",
      "citations": ["sarparast_2022"]
    },
    {
      "id": "interaction_mdma_polydrug_001",
      "drug1": "MDMA",
      "drug2": "Multiple substances",
      "severity": "very_high",
      "description": "Polydrug use dramatically increases adverse effects",
      "commonCombinations": [
        {
          "substance": "alcohol",
          "prevalence": "81% of users",
          "risks": ["dehydration", "impaired_judgment", "increased_toxicity"]
        },
        {
          "substance": "stimulants",
          "risks": ["severe_cardiovascular_stress", "hyperthermia"]
        },
        {
          "substance": "cannabis",
          "prevalence": "common"
        }
      ],
      "deathStatistics": {
        "value": 66,
        "unit": "percent",
        "context": "MDMA deaths in England/Wales involved another drug besides alcohol"
      },
      "citations": ["sarparast_2022", "makunts_2023", "atila_2024", "edwards_2023"]
    }
  ],

  "routesOfAdministration": [
    {
      "id": "roa_mdma_oral_001",
      "route": "Oral",
      "status": "most_common",
      "description": "Primary route for both recreational and therapeutic use",
      "forms": ["tablets", "capsules", "powder", "crystals"],
      "onset": {"min": 30, "max": 60, "unit": "minutes"},
      "peak": {"min": 60, "max": 120, "unit": "minutes"},
      "duration": {"min": 3, "max": 6, "unit": "hours"},
      "advantages": [
        "Convenient",
        "Predictable onset",
        "Standard for clinical use"
      ],
      "risks": [
        {
          "risk": "hyponatremia",
          "context": "Especially in hot environments with dancing",
          "mechanism": "Overhydration with hypotonic fluids",
          "citations": ["edwards_2023", "barnett_2021", "malcolm_2022"]
        },
        {
          "risk": "hyperthermia",
          "context": "Nightclubs, festivals",
          "mechanism": "Prolonged dancing in hot environments",
          "citations": ["barnett_2021"]
        }
      ],
      "citations": ["edwards_2023", "henriquez_2023"]
    },
    {
      "id": "roa_mdma_intranasal_001",
      "route": "Intranasal (Insufflation)",
      "status": "less_common",
      "description": "Being explored in clinical settings",
      "onset": "Potentially faster than oral",
      "duration": "Potentially shorter than oral",
      "advantages": [
        "Faster onset",
        "Shorter duration of action"
      ],
      "risks": [
        {
          "risk": "potential_for_misuse",
          "severity": "elevated",
          "context": "In real-world settings lacking supervision",
          "citation": "sapkota_2021"
        },
        {
          "risk": "increased_road_traffic_accidents",
          "mechanism": "Dissociation and impaired hand-eye coordination",
          "citation": "sapkota_2021"
        },
        {
          "risk": "elevated_blood_pressure",
          "consequence": "May increase risk of heart failure and MI",
          "citation": "sapkota_2021"
        },
        {
          "risk": "nasal_irritation",
          "severity": "mild_to_moderate"
        }
      ],
      "limitedData": true,
      "citations": ["rucker_2024", "sapkota_2021"]
    },
    {
      "id": "roa_mdma_other_001",
      "route": "Other Routes",
      "types": ["intravenous", "intramuscular", "rectal", "sublingual", "inhalation"],
      "status": "rare",
      "description": "Not well-studied routes",
      "risks": [
        "Rapid onset potentially increasing acute adverse reactions",
        "Unpredictable effects",
        "Unknown safety profile"
      ],
      "note": "May lead to more rapid onset, increasing risk",
      "citations": ["rucker_2024", "henriquez_2023", "dourron_2023"]
    }
  ],

  "qualityContaminationFactors": [
    {
      "id": "contam_mdma_variability_001",
      "name": "Variable MDMA Content",
      "category": "quality",
      "severity": "high",
      "description": "Amount of MDMA in tablets varies significantly",
      "prevalence": {
        "actualMDMA": {
          "value": 63,
          "unit": "percent",
          "description": "Pills contained MDMA or related analog"
        },
        "otherDrugs": {
          "value": 29,
          "unit": "percent",
          "description": "Pills contained other identifiable drugs"
        }
      },
      "trends": {
        "increasingPotency": "Average MDMA content increasing over past decade",
        "megadoses": "Often 2-3x typical recreational dose",
        "highDosePills": "Up to 300mg/pill documented"
      },
      "consequences": [
        "Difficult to gauge dosage",
        "Increased risk of accidental overdose",
        "Unpredictable effects"
      ],
      "citations": ["edwards_2023", "banta-green_2005"]
    },
    {
      "id": "contam_mdma_adulterants_001",
      "name": "Adulteration",
      "category": "contamination",
      "severity": "critical",
      "description": "Pills sold as MDMA may contain other substances",
      "commonAdulterants": [
        {
          "adulterant": "PMMA",
          "fullName": "paramethoxymethamphetamine",
          "risk": "More toxic than MDMA",
          "outcome": "Fatalities documented",
          "citation": "haden_2016"
        },
        {
          "adulterant": "fentanyl",
          "risk": "Overdose and death",
          "prevalence": "Significant concern",
          "citation": "rajwani_2022"
        },
        {
          "adulterant": "other_opioids",
          "risk": "Overdose and death"
        },
        {
          "adulterant": "NBOMe_compounds",
          "risk": "Severe toxicity"
        },
        {
          "adulterant": "cathinones",
          "risk": "Unpredictable effects"
        }
      ],
      "citations": ["haden_2016", "rajwani_2022", "edwards_2023"]
    },
    {
      "id": "contam_mdma_sourcing_001",
      "name": "Unregulated Market Sourcing",
      "category": "sourcing",
      "severity": "high",
      "description": "Illicit MDMA lacks quality control",
      "risks": [
        "Unknown purity",
        "Variable potency",
        "Presence of adulterants",
        "Misrepresentation",
        "No safety guarantees"
      ],
      "consequences": [
        "Unpredictable effects",
        "Increased toxicity risk",
        "Difficulty with safe dosing"
      ],
      "citations": ["edwards_2023", "haden_2016"]
    },
    {
      "id": "contam_mdma_testing_001",
      "name": "Lack of Testing",
      "category": "harm_reduction",
      "severity": "moderate",
      "description": "Limited access to drug testing",
      "issues": [
        "Drug test kits unreliable",
        "Cannot detect all adulterants",
        "Cannot accurately measure amount",
        "Cannot predict individual response"
      ],
      "solutions": [
        "Drug checking services",
        "Reagent testing",
        "Trusted sources",
        "Test doses"
      ]
    }
  ],

  "harmReductionStrategies": [
    {
      "id": "hr_mdma_001",
      "strategy": "Dose Management",
      "practices": [
        "Start with lower doses",
        "Avoid redosing",
        "Be aware that non-linear kinetics make redosing especially dangerous",
        "Understand pills may contain 2-3x expected dose"
      ]
    },
    {
      "id": "hr_mdma_002",
      "strategy": "Hydration Management",
      "practices": [
        "Avoid overhydration",
        "Limit to ~500mL water per hour",
        "Avoid hypotonic fluids",
        "Consider fluid restriction strategies in clinical settings"
      ],
      "rationale": "Prevent hyponatremia",
      "citations": ["atila_2024", "barnett_2021"]
    },
    {
      "id": "hr_mdma_003",
      "strategy": "Temperature Management",
      "practices": [
        "Avoid hot environments",
        "Take cooling breaks",
        "Monitor body temperature",
        "Reduce physical exertion"
      ],
      "rationale": "Prevent hyperthermia",
      "citations": ["curry_2018", "barnett_2021"]
    },
    {
      "id": "hr_mdma_004",
      "strategy": "Avoid Polydrug Use",
      "emphasis": "critical",
      "avoid": [
        "Alcohol",
        "Stimulants",
        "SSRIs",
        "MAOIs (absolute)",
        "Other serotonergic drugs"
      ],
      "rationale": "Dramatically reduces risk of adverse events and death"
    },
    {
      "id": "hr_mdma_005",
      "strategy": "Substance Testing",
      "practices": [
        "Use reagent test kits",
        "Access drug checking services where available",
        "Take test doses",
        "Purchase from trusted sources"
      ]
    },
    {
      "id": "hr_mdma_006",
      "strategy": "Setting Management",
      "practices": [
        "Use in safe, controlled environments",
        "Have trusted support person present",
        "Avoid situations requiring driving or machinery operation",
        "Ensure access to medical care if needed"
      ]
    },
    {
      "id": "hr_mdma_007",
      "strategy": "Frequency Limitation",
      "practice": "Avoid regular/frequent use",
      "rationale": "Reduce neurotoxicity and dependence risk",
      "recommendation": "Minimum several weeks between uses"
    }
  ],

  "emergencyResponseProtocols": [
    {
      "id": "emergency_mdma_hyponatremia_001",
      "condition": "Hyponatremia",
      "severity": "critical",
      "recognition": [
        "Confusion",
        "Nausea/vomiting",
        "Headache",
        "Muscle weakness",
        "Seizures (severe)"
      ],
      "immediateActions": [
        "Stop fluid intake",
        "Seek immediate medical attention",
        "Monitor vital signs",
        "Hospital admission for severe cases"
      ],
      "treatment": [
        "Fluid restriction",
        "Hypertonic saline if severe",
        "Electrolyte monitoring",
        "ICU care if needed"
      ]
    },
    {
      "id": "emergency_mdma_hyperthermia_001",
      "condition": "Hyperthermia",
      "severity": "critical",
      "recognition": [
        "Body temperature >40°C (104°F)",
        "Confusion",
        "Rapid heart rate",
        "Dry skin or profuse sweating"
      ],
      "immediateActions": [
        "Move to cool environment",
        "Remove excess clothing",
        "Apply cooling measures (ice packs, cool water)",
        "Call emergency services",
        "Monitor vital signs continuously"
      ],
      "citations": ["curry_2018"]
    },
    {
      "id": "emergency_mdma_serotonin_syndrome_001",
      "condition": "Serotonin Syndrome",
      "severity": "critical",
      "recognition": [
        "Agitation",
        "Confusion",
        "Rapid heart rate",
        "High blood pressure",
        "Muscle rigidity",
        "Tremor",
        "Hyperthermia"
      ],
      "immediateActions": [
        "Discontinue all serotonergic agents",
        "Call emergency services",
        "Supportive care",
        "Benzodiazepines for agitation",
        "Cooling measures",
        "IV fluids"
      ],
      "treatment": [
        "ICU admission if severe",
        "Serotonin antagonists (cyproheptadine)",
        "Intubation if needed"
      ]
    }
  ],

  "therapeuticConsiderations": {
    "mdmaAssistedPsychotherapy": {
      "indication": "PTSD (FDA breakthrough therapy designation)",
      "format": "MDMA administered in conjunction with psychotherapy",
      "sessions": "Typically 2-3 MDMA sessions with preparatory and integration sessions",
      "mechanism": "Empathogenic effects facilitate therapeutic processing of trauma",
      "evidence": "Strong from clinical trials",
      "otherApplications": ["anxiety", "depression", "relationship issues"]
    },
    "clinicalProtocols": {
      "screening": "Comprehensive medical and psychiatric screening required",
      "preparation": "Multiple preparation sessions to build therapeutic alliance",
      "session": [
        "Comfortable, safe environment",
        "Two therapists present",
        "Continuous monitoring",
        "Support as needed"
      ],
      "integration": "Multiple integration sessions following MDMA session",
      "monitoring": [
        "Vital signs",
        "Hydration status",
        "Psychological state",
        "Body temperature"
      ]
    }
  },

  "researchGaps": [
    "Long-term effects of therapeutic MDMA use",
    "Optimal dosing protocols",
    "Individual differences in response",
    "Mechanisms of neurotoxicity in humans",
    "Long-term cognitive effects",
    "Sex differences in effects and risks",
    "Genetic factors influencing response",
    "Comparative safety of different routes of administration",
    "Effectiveness of harm reduction strategies",
    "Prevention and treatment of comedown/blues"
  ],

  "metadata": {
    "substanceName": "MDMA",
    "schemaCreatedFrom": "Psychedelic Safety Institute Literature Review",
    "primarySources": "400+ citations",
    "lastUpdated": "2025-01-09",
    "coverageQuality": "comprehensive_clinical_and_observational",
    "knownLimitations": [
      "Limited diversity in research populations",
      "Underreporting of adverse events likely in recreational contexts",
      "Variable methodology across studies",
      "Limited long-term follow-up data",
      "Most data from controlled settings; naturalistic use less studied"
    ]
  }
}